Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

No Easy Task But Insulet Determined To Fly Solo In Europe

Executive Summary

After eight years together, Insulet will be splitting from its exclusive European distributor Ypsomed and take full responsibility for the distribution, sales, marketing, training and support activities of its Omnipod insulin management system in that region. Insulet's president and chief operating officer, Shacey Petrovic told Medtech Insight how the Massachusetts-based company will embark on this next solo chapter.

You may also be interested in...



ADA2018: Insulet Reports Positive Clinical Results For Omnipod Horizon, Limited Market Release Of Dash

Insulet Corp. plans a limited market release in the second half of this year of its recently FDA-cleared Omnipod Dash Insulin Management System through the pharmacy channel. Results from the most recent clinical trial supporting the Omnipod hybrid closed-loop system were presented this week's American Diabetes Association meeting in Orlando.

Insulet, Ypsomed Split Up And Go Head-To-Head In Insulin Pump Market

Insulin pump commercial partners Insulet and Ypsomed will be parting ways after some eight years in an exclusive distribution alliance. The companies failed to reach an agreement to renew the distributor agreement, which will end June 2018, following differences on price. Ypsomed announced it will introduce its own tubeless insulin pump in the mid-term.

Market Intel: Advent Of Artificial Pancreas Tech To Galvanize Fast-Growing Diabetes Market

The global diabetes management devices market is expected to exceed $11.2bn by 2020, driven largely by the rising diabetes epidemic. This, in turn, is fueling significant innovation such as next-generation, automated artificial pancreas systems and miniaturized, less-invasive wireless technologies that can continuously track and analyze glucose levels in real-time. This feature looks more closely at these and other potentially groundbreaking new technologies, as well as the competitive landscape of the two major product segments – insulin pumps and blood glucose monitors.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT105227

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel